Drug Profile
ACTR 707
Alternative Names: ACTR707Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Unum Therapeutics
- Developer Cogent Biosciences
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Parenteral)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Second-line therapy or greater) in USA (Parenteral)
- 05 Oct 2020 Unum Therapeutics is now called Cogent Biosciences